INTRODUCTION:Dysphagia is a common, dose-limiting toxicity of combined chemoradiotherapy (CT/RT) in patients with locally advanced non-small cell lung cancer (NSCLC). This study assessed the efficacy and safety of palifermin in reducing dysphagia from CT/RT followed by consolidation chemotherapy (CT). METHODS: This randomized, double-blind, phase II trial enrolled adults with unresectable stage III NSCLC. Subjects received weekly paclitaxel (50 mg/m2) and carboplatin (AUC 2.0) with concurrent daily radiation (RT) of 6000 to 6600 cGy, followed by consolidation CT. Palifermin (n = 49) or placebo (n = 46) was administered before starting concurrent CT/RT and once weekly for 6 weeks. The primary end points were the incidence of grade ≥ 2 dysphagia and safety. RESULTS: The incidence of grade ≥ 2 and ≥ 3 dysphagia was numerically lower in palifermin subjects versus placebo subjects (61% versus 70%; p = 0.36; 22% versus 28%, p = 0.50, respectively). Mean duration of dysphagia (grade ≥ 2) was 25 days for palifermin subjects and 32 days for placebo subjects (p = 0.32). The incidence of adverse events was similar in the two treatment groups, and median overall survival and progression-free survival were not adversely affected by palifermin treatment (overall survival: 513 versus 319 days; progression-free survival: 262 versus 235 days for palifermin versus placebo arms, respectively). The palifermin arm received more doses of CT per study design and significantly more patients received RT doses ≥ 6000 cGy (84% versus 61%, p = 0.01). CONCLUSIONS: The results of this exploratory trial suggest that additional larger studies may be warranted to further evaluate the effect of palifermin on dysphagia, exposure to CT/RT, and long-term survival.
RCT Entities:
INTRODUCTION:Dysphagia is a common, dose-limiting toxicity of combined chemoradiotherapy (CT/RT) in patients with locally advanced non-small cell lung cancer (NSCLC). This study assessed the efficacy and safety of palifermin in reducing dysphagia from CT/RT followed by consolidation chemotherapy (CT). METHODS: This randomized, double-blind, phase II trial enrolled adults with unresectable stage III NSCLC. Subjects received weekly paclitaxel (50 mg/m2) and carboplatin (AUC 2.0) with concurrent daily radiation (RT) of 6000 to 6600 cGy, followed by consolidation CT. Palifermin (n = 49) or placebo (n = 46) was administered before starting concurrent CT/RT and once weekly for 6 weeks. The primary end points were the incidence of grade ≥ 2 dysphagia and safety. RESULTS: The incidence of grade ≥ 2 and ≥ 3 dysphagia was numerically lower in palifermin subjects versus placebo subjects (61% versus 70%; p = 0.36; 22% versus 28%, p = 0.50, respectively). Mean duration of dysphagia (grade ≥ 2) was 25 days for palifermin subjects and 32 days for placebo subjects (p = 0.32). The incidence of adverse events was similar in the two treatment groups, and median overall survival and progression-free survival were not adversely affected by palifermin treatment (overall survival: 513 versus 319 days; progression-free survival: 262 versus 235 days for palifermin versus placebo arms, respectively). The palifermin arm received more doses of CT per study design and significantly more patients received RT doses ≥ 6000 cGy (84% versus 61%, p = 0.01). CONCLUSIONS: The results of this exploratory trial suggest that additional larger studies may be warranted to further evaluate the effect of palifermin on dysphagia, exposure to CT/RT, and long-term survival.
Authors: C A Perez; K Stanley; P Rubin; S Kramer; L Brady; R Perez-Tamayo; G S Brown; J Concannon; M Rotman; H G Seydel Journal: Cancer Date: 1980-06-01 Impact factor: 6.860
Authors: C L Farrell; J V Bready; K L Rex; J N Chen; C R DiPalma; K L Whitcomb; S Yin; D C Hill; B Wiemann; C O Starnes; A M Havill; Z N Lu; S L Aukerman; G F Pierce; A Thomason; C S Potten; T R Ulich; D L Lacey Journal: Cancer Res Date: 1998-03-01 Impact factor: 12.701
Authors: M B Hazuka; A T Turrisi; S T Lutz; M K Martel; R K Ten Haken; M Strawderman; P L Borema; A S Lichter Journal: Int J Radiat Oncol Biol Phys Date: 1993-09-30 Impact factor: 7.038
Authors: Ritsuko Komaki; Jin Soo Lee; Luka Milas; Hoon K Lee; Frank V Fossella; Roy S Herbst; Pamela K Allen; Zhongxing Liao; Craig W Stevens; Charles Lu; Ralph G Zinner; Vassiliki A Papadimitrakopoulou; Merrill S Kies; George R Blumenschein; Katherine M Pisters; Bonnie S Glisson; Johnathan Kurie; Bunyamin Kaplan; Veronica P Garza; Deidre Mooring; Susan L Tucker; James D Cox Journal: Int J Radiat Oncol Biol Phys Date: 2004-04-01 Impact factor: 7.038
Authors: Saroj Vadhan-Raj; Jenna D Goldberg; Miguel-Angel Perales; Dietmar P Berger; Marcel R M van den Brink Journal: J Cell Mol Med Date: 2013-11-19 Impact factor: 5.310